Patents Assigned to Molecular Targeting Technologies, Inc.
  • Anti-thrombotic agents and methods of use thereof
    Patent number: 11090309
    Abstract: The present invention is related to compositions and methods for treating platelet-related diseases.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: August 17, 2021
    Assignees: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Molecular Targeting Technologies. Inc.
    Inventors: Parkson L-G Chong, Lawrence E. Goldfinger, Koon Y. Pak, Brian D. Gray
  • Dipicolylamine derivatives and their pharmaceutical uses
    Patent number: 9388193
    Abstract: Dipicolylamine compounds of Formula (I) set forth herein. Also disclosed are pharmaceutical compositions containing metal ions and these compounds. Further disclosed is a method for treating a condition associated with cells containing inside-out phosphatidylserine, with these compounds.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: July 12, 2016
    Assignees: National Health Research Institutes, Molecular Targeting Technologies, Inc.
    Inventors: Chiung-Tong Chen, Kak-Shan Shia, Chien-Huang Wu, Lun-Kelvin Tsou, Yu-Sheng Chao
  • Molecular probes for multimodality imaging of anionic membrane surfaces
    Patent number: 9211349
    Abstract: Embodiments provide dual modality probes for imaging phosphatidylserine (PS) exposure and other anionic membrane surfaces. In various embodiments, the probes were constructed by utilizing a) the high selectivity of synthetic zinc (II) dipicolylamine coordination complexes (Zn-DPA) for targeting externalized PS which over-expresses in apoptotic and necrotic cells, b) a near-infrared (NIR) dye for optical imaging, and c) a widely used clinically approved radionuclide for PET (or SPECT) imaging. A variety of linking elements were incorporated into the probes between the Zn-DPA and radionuclide motif to modulate the pharmacokinetics. The in vitro and in vivo data of radiolabeled dipicolylamine probes demonstrated their utilities for imaging PS exposure with multiple imaging modalities.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: December 15, 2015
    Assignee: Molecular Targeting Technologies, Inc.
    Inventors: Brian Gray, Kai Chen, Koon Y. Pak
  • High performance luminescent compounds
    Patent number: 8273875
    Abstract: Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to novel near-infrared dyes that are photostable and resistant to quenching. The dyes belong to a novel family of squaraine rotaxanes, and they are particularly well-suited for use in biological applications. Also disclosed are methods of synthesizing the dyes and methods of using the dyes.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: September 25, 2012
    Assignees: University of Notre Dame du Lac, Molecular Targeting Technologies, Inc.
    Inventors: Bradley Smith, Arunkumar Easwaran
  • HIGH PERFORMANCE LUMINESCENT COMPOUNDS
    Publication number: 20110118459
    Abstract: Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to novel near-infrared dyes that are photostable and resistant to quenching. The dyes belong to a novel family of squaraine rotaxanes, and they are particularly well-suited for use in biological applications. Also disclosed are methods of synthesizing the dyes and methods of using the dyes.
    Type: Application
    Filed: November 16, 2009
    Publication date: May 19, 2011
    Applicants: University of Notre Dame du Lac, Molecular Targeting Technologies, Inc.
    Inventors: Bradley Smith, Arunkumar Easwaran